Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [467]
News [1266]
Articles [16]
Editorials [1]
Conferences [112]
elearning [2]
HER2DX confirms the ability of the test to predict long-term survival and...
Prof Aleix Prat - Hospital Clínic Barcelona, Barcelona, Spain
HER2DX confirms the ability of the test to predict long-term survival and response to anti-HER2 therapy in BC ( Prof Aleix Prat - Hospital Clínic Barcelona, Barcelona, Spain )
9 Dec 2022
Cancer control in Latin America
Adolfo Dammert - Liga Contra el Cáncer, Pueblo Libre, Perú
Cancer control in Latin America ( Adolfo Dammert - Liga Contra el Cáncer, Pueblo Libre, Perú )
22 Nov 2022
Assessment of cervical and breast cancer screening in Latin America and...
Dr Isabel Mosquera - International Agency for Research on Cancer, Lyon, France
Assessment of cervical and breast cancer screening in Latin America and Caribbean: CanScreen5/CELAC project ( Dr Isabel Mosquera - International Agency for Research on Cancer, Lyon, France )
21 Nov 2022
ESMO 2022: Highlights, commentary and analysis
Dr Bishal Gyawali - Queen's University, Kingston, Canada
ESMO 2022: Highlights, commentary and analysis ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
12 Sep 2022
Sotorasib shows superior PFS and ORR compared to docetaxel for NSCLC
Dr Silvia Novello - University of Turin, Turin, Italy
Sotorasib shows superior PFS and ORR compared to docetaxel for NSCLC ( Dr Silvia Novello - University of Turin, Turin, Italy )
12 Sep 2022
ESMO 2022: Renal roundup
Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
ESMO 2022: Renal roundup ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )
12 Sep 2022
ESMO 2022: Breast cancer highlights
Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy
ESMO 2022: Breast cancer highlights ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )
12 Sep 2022
Cabozantinib in combination w/ nivolumab and ipilimumab of IMDC intermediate or...
Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
Cabozantinib in combination w/ nivolumab and ipilimumab of IMDC intermediate or poor risk significantly improved PFS vs PBO ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )
12 Sep 2022
Lenvatinib plus pembro for aRCC - update on the CLEAR study
Dr Bradley McGregor - Dana-Farber Cancer Institute, Boston, USA
Lenvatinib plus pembro for aRCC - update on the CLEAR study ( Dr Bradley McGregor - Dana-Farber Cancer Institute, Boston, USA )
12 Sep 2022
Abemaciclib plus NSAI for HR+, HER2- advanced breast cancer - MONARCH 3 interim...
Prof Matthew P Goetz - Mayo Clinic, Rochester, USA
Abemaciclib plus NSAI for HR+, HER2- advanced breast cancer - MONARCH 3 interim data ( Prof Matthew P Goetz - Mayo Clinic, Rochester, USA )
12 Sep 2022
Optimum treatment strategy algorithm for mCRC
Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA
Optimum treatment strategy algorithm for mCRC ( Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA )
15 Aug 2022
Lung cancer immunotherapy adjuvant and neoadjuvant indications
Dr. Luis Raez - Memorial Healthcare System, Florida, USA
Lung cancer immunotherapy adjuvant and neoadjuvant indications ( Dr. Luis Raez - Memorial Healthcare System, Florida, USA )
8 Jul 2022

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation